Associated equity: OSE Immunotherapeutics
OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.
OSE Immunotherapeutics — 9 videos in collection
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes and Paris, France, and listed on Euronext Paris. The company is developing innovative immunotherapies across immuno-oncology and immuno-inflammation, with a renewed strategy focused on advancing its two lead proprietary clinical assets, Tedopi and lusvertikimab. This sharpened approach is designed to concentrate resources on programmes with the clearest potential to create value over the next several years.
We highlight four key points of OSE’s investment story.
For further details, please refer to our latest research on OSE Immunotherapeutics.